By Counterforce Health Team in Givlaari (givosiran) —

Myths vs. Facts: Getting Givlaari (givosiran) Covered by Aetna (CVS Health) in New Jersey

Answer Box: Getting Givlaari Covered by Aetna in New Jersey

Eligibility: Confirmed acute hepatic porphyria (AHP) with elevated urine PBG/ALA levels and documented attacks requiring hospitalization or IV hemin. Fastest path: Have your porphyria specialist submit prior authorization with lab results, attack history, and medical necessity letter to CVS Caremark Specialty (866-814-5506). First step today: Gather your biochemical confirmation results and recent attack documentation—these are non-negotiable requirements that many patients miss.

Table of Contents

  1. Why Myths About Givlaari Coverage Persist
  2. Myth vs. Fact: Common Misconceptions
  3. What Actually Influences Approval
  4. Avoid These Preventable Mistakes
  5. Quick Action Plan: Three Steps to Take Today
  6. Resources and Forms

Why Myths About Givlaari Coverage Persist

Givlaari (givosiran) represents a breakthrough for acute hepatic porphyria patients, but its $575,000+ annual cost and complex approval process have spawned countless myths about insurance coverage. These misconceptions often delay treatment for months while patients navigate unnecessary steps or give up entirely.

The confusion stems from several factors: Aetna's strict prior authorization criteria aren't widely understood, the rare disease community relies heavily on word-of-mouth advice, and many primary care physicians haven't encountered AHP coverage requirements before.

In New Jersey, where patients have robust appeal rights through the Independent Health Care Appeals Program (IHCAP), understanding the real requirements can mean the difference between approval and a lengthy denial process.

Myth vs. Fact: Common Misconceptions

Myth 1: "If my doctor prescribes Givlaari, Aetna has to cover it"

Fact: Prescription alone doesn't guarantee coverage. Aetna requires specific prior authorization criteria including confirmed AHP diagnosis with elevated urine porphobilinogen (PBG) or porphyrin levels, plus documented attacks requiring hospitalization, urgent care, or IV hemin—or four or more attacks per year.

Myth 2: "I need to try cheaper medications first (step therapy)"

Fact: Givlaari doesn't typically require step therapy because there are no equivalent chronic AHP preventive therapies. However, Aetna does require documentation of your attack history and may ask about previous hemin use for acute episodes.

Myth 3: "Genetic testing isn't necessary if I have symptoms"

Fact: While symptoms matter, Aetna's policy requires either elevated urine PBG or elevated porphyrin levels in plasma/feces. Genetic confirmation strengthens your case but biochemical evidence is the foundation of approval.

Myth 4: "Appeals take forever and rarely work"

Fact: In New Jersey, internal appeals must be decided within 30 days for standard requests, 72 hours for expedited cases. External appeals through IHCAP are decided within 45 days (48 hours if expedited). About half of external appeals favor patients nationwide.

Myth 5: "I can get Givlaari from any pharmacy once approved"

Fact: Givlaari is a specialty medication available only through designated specialty pharmacies like CVS Caremark Specialty. You'll need to coordinate with their team for delivery and clinical monitoring.

Myth 6: "My primary care doctor can handle the prior authorization"

Fact: While any licensed physician can prescribe Givlaari, porphyria specialists have higher approval rates because they understand the specific clinical documentation Aetna requires and can provide more compelling medical necessity letters.

Myth 7: "If I'm denied once, I can't reapply"

Fact: You can resubmit with additional documentation, appeal the denial, or request a formulary exception. New Jersey patients also have access to external review through IHCAP if internal appeals fail.

Myth 8: "Aetna covers Givlaari differently in New Jersey than other states"

Fact: Aetna's medical policy for Givlaari is consistent across states, but New Jersey patients have stronger appeal rights and external review options through state regulations.

What Actually Influences Approval

Understanding what Aetna actually evaluates can dramatically improve your chances of approval:

Clinical Documentation Requirements

  • Biochemical confirmation: Elevated urine ALA and PBG levels during or after an attack
  • Attack frequency: Documentation of attacks requiring hospitalization, urgent care, or IV hemin administration
  • Specialist involvement: Letters from hematologists, gastroenterologists, or porphyria specialists carry more weight
  • Treatment goals: Clear documentation of how Givlaari will reduce attack frequency and improve quality of life

Administrative Factors

  • Complete forms: Missing fields on the Aetna precertification request cause automatic delays
  • Proper routing: Specialty medications require submission to CVS Caremark Specialty (866-814-5506), not standard pharmacy benefits
  • Timing: Requests submitted with all documentation move faster than incomplete submissions requiring follow-up

Medical Necessity Elements

Aetna's clinical reviewers look for evidence that Givlaari is medically necessary based on:

  • FDA-approved indication for AHP
  • Patient's specific AHP subtype and severity
  • Impact of current attack frequency on daily functioning
  • Lack of adequate response to standard supportive care

Avoid These Preventable Mistakes

These five errors account for most initial denials:

1. Submitting Without Biochemical Proof

Many requests lack recent urine ALA/PBG results or plasma porphyrin levels. Collect these during or immediately after an attack when levels are highest.

2. Insufficient Attack Documentation

"Frequent attacks" isn't enough. Aetna needs specific dates, hospital admissions, ER visits, or hemin administration records. Keep a detailed attack diary with medical records.

3. Wrong Submission Route

Sending specialty drug requests through standard pharmacy channels causes delays. Always use the specialty pharmacy prior authorization process.

4. Incomplete Medical Necessity Letters

Generic letters often fail. Include patient-specific details: attack frequency, triggers, impact on work/family, previous treatments tried, and why Givlaari is the appropriate next step.

5. Missing Follow-Up

Don't assume no news is good news. Track your request status and respond promptly to requests for additional information.

From our advocates: We've seen cases where patients waited months for a decision, only to discover their request was denied for missing lab values that could have been provided within days. One patient's approval was delayed six weeks because their physician submitted the request to standard pharmacy benefits instead of CVS Caremark Specialty. These administrative errors are completely preventable with proper preparation.

Quick Action Plan: Three Steps to Take Today

Step 1: Gather Your Documentation (Today)

  • Insurance card with member ID and group number
  • Recent urine ALA/PBG results (within past 12 months)
  • Hospital records or ER visit summaries for recent attacks
  • List of all AHP-related medications tried, including hemin
  • Contact information for your prescribing physician

Step 2: Coordinate with Your Specialist (This Week)

  • Schedule appointment with hematologist, gastroenterologist, or porphyria specialist if you don't have one
  • Request they complete Aetna's precertification form
  • Ask for detailed medical necessity letter addressing your specific attack pattern and treatment history

Step 3: Submit and Track (Within 2 Weeks)

  • Have your physician submit to CVS Caremark Specialty: 866-814-5506 (phone) or 866-249-6155 (fax)
  • Request confirmation of receipt and timeline for decision
  • Mark your calendar for follow-up if you don't hear back within the expected timeframe

Resources and Forms

Key Aetna/CVS Health Resources

New Jersey Appeals Resources

Patient Support Programs

  • Alnylam Assist Program for Givlaari patient support
  • American Porphyria Foundation: Resources and advocacy support
  • Counterforce Health: Specialized insurance appeal assistance for complex medications like Givlaari

Clinical Resources

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Coverage decisions depend on individual circumstances and plan benefits. Always consult with your healthcare provider and insurance plan for specific guidance. For personalized assistance with complex insurance appeals, consider consulting with specialists like Counterforce Health, who help patients navigate prior authorization and appeals processes for specialty medications.

Last updated: Based on current Aetna policies and New Jersey regulations as of 2024. Verify current requirements with your specific plan.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.